Severe neurotoxicity, ototoxicity and nephrotoxicity following high-dose cisplatin and amifostine.
Cisplatin in higher doses have been used routinely in the treatment of childhood tumours including neuroblastoma and germ cell tumors. Amifostine, a broad-spectrum cytoprotector of normal tissues, has been approved by U.S. Food and Drug Administration for use in patients receiving cisplatin. Such administration of amifostine has been reported to reduce cisplatin-related toxicities in some studies, but not all. The authors report a case of severe toxicity with cisplatin in a girl with epithelial cell carcinoma of the ovary despite the use of amifostine.
Sastry
Jairam
J
Oncology Unit, The Children's Hospital at Westmead, and Discipline of Paediatrics and Child Health at the University of Sydney, Sydney, NSW, Australia. jairamsastry@hotmail.com
Kellie
Stewart J
SJ
D000293:Adolescent; D004999:Amifostine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D002277:Carcinoma / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017809:Fatal Outcome; D005260:Female; D006309:Hearing / Q000187:drug effects*; D006801:Humans; D007275:Injections, Intravenous; D007668:Kidney / Q000187:drug effects*; D009420:Nervous System / Q000187:drug effects*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012008:Recurrence; D016896:Treatment Outcome
D004999:Amifostine; D002945:Cisplatin